Valtecne (VLT) H1 2024 earnings summary

Executive summary

• First half of 2024 marked by stable revenues (€17.1M, +0.4% YoY), with a strategic shift toward the Medical Devices segment, now 68.3% of sales (+15.7% YoY), while Industrial declined 21.9% YoY.

• EBITDA margin improved to 23.7% (vs. 23.2% in H1 2023), despite a 7.4% drop in production value and a 7% decrease in net profit (€2.19M).

• Net cash position strengthened to €4.4M (from €2.4M at 31/12/2023), supporting future M&A ambitions.

Financial highlights

• Revenues: €17.08M (H1 2024), stable YoY.

• EBITDA: €3.75M (-5.7% YoY); EBITDA margin: 23.7%.

• EBIT: €2.91M (-11.1% YoY); Net profit: €2.19M (-7.0% YoY).

• Net financial position: €4.39M cash (vs. €2.36M at 31/12/2023).

• Capex focused on production assets; tangible fixed assets up 7.4% to €7.66M.

Outlook and guidance

• Medical Devices expected to continue strong growth, supported by robust order backlog and ongoing investments.

• Industrial segment likely to remain weak through year-end, with stabilization but no short-term recovery.

• Full-year 2024 results expected broadly in line with 2023, barring unforeseen risks.

• M&A activity remains a strategic priority, with ample liquidity for acquisitions.